FeaturedOncology

Tarlatamab (Imdelltra)

Amgen

DLL3 × CD3 bispecific T-cell engager. FDA approved for 2L SCLC. DeLLphi-304 Phase 3 confirmatory trial met OS primary endpoint April 2025 — full approval expected.

Small Cell Lung Cancer

Linked Studies

NCT05740566PrimaryACTIVE_NOT_RECRUITINGPHASE3

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer (SCLC)Updated Jan 2026

Loading comments…

Also Known As

Other names

tarlatamab

Search all trials →Request coverage update